4551.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Šios dienos apimtis	48 200.00
Vidutinė apimtis	31 521.00
Rinkos kapitalizacija	108.35B
EPS	¥0 ( 2024-04-25 )
Last Dividend	¥50.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	26.32
ATR14	¥5.18 (0.13%)

Tūris Koreliacija

Ilgas: 0.15 (neutral)

Trumpas: 0.40 (neutral)

Signal:(54.642) Neutral

Torii Pharmaceutical Co., Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Torii Pharmaceutical Co., Koreliacija - Valiuta/Žaliavos

0.94
( very strong )

0.65
( weak )

0.86
( strong )

-0.75
( moderate negative )

-0.87
( strong negative )

Torii Pharmaceutical Co., Finansinės ataskaitos

Annual	2023
Pajamos:	¥54.64B
Bruto pelnas:	¥24.57B (44.97 %)
EPS:	¥146.57

FY	2023
Pajamos:	¥54.64B
Bruto pelnas:	¥24.57B (44.97 %)
EPS:	¥146.57

FY	2022
Pajamos:	¥48.89B
Bruto pelnas:	¥23.38B (47.81 %)
EPS:	¥140.38

FY	2021
Pajamos:	¥46.99B
Bruto pelnas:	¥24.34B (51.80 %)
EPS:	¥32.16

Financial Reports:

No articles found.

Torii Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥76.00 (N/A)	¥0 (N/A)	¥50.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Torii Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 7.39 - good (73.87%) | Divividend Growth Potential Score: 3.44 - Decrease likely (31.16%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥2.00	2001-03-27
Last Dividend	¥50.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	¥907.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.09	--
Div. Sustainability Score	7.39
Div.Growth Potential Score	3.44
Div. Directional Score	5.41	--

Next Divdend (Est)
(2024-09-25)

¥0 Estimate 3.76 %

Dividend Stability

0.30 Poor

Dividend Score

3.09

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7088.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6378.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5304.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4368.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3538.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
2763.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9658.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8600.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
8182.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7564.T	Ex Dividend Knight	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0939	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0398	1.200	8.67	10.00	[0 - 0.3]
returnOnEquityTTM	0.0444	1.500	-0.618	-0.927	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.50	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.20	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.280	1.500	9.56	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.448	1.000	5.86	5.86	[0.2 - 0.8]
operatingProfitMarginTTM	0.122	1.000	9.56	9.56	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.423	0.800	-0.511	-0.409	[0.5 - 2]
Total Score				7.39

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.50	1.000	8.03	0	[1 - 100]
returnOnEquityTTM	0.0444	2.50	-0.397	-0.927	[0.1 - 1.5]
freeCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.11	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.448	1.500	-0.349	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0163	1.000	-2.09	0	[0.1 - 0.5]
Total Score				3.44

Torii Pharmaceutical Co.,

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.